Advertisement
UK markets close in 7 hours 43 minutes

  • FTSE 100

    8,126.54
    +47.68 (+0.59%)
     

  • FTSE 250

    19,723.62
    +121.64 (+0.62%)
     

  • AIM

    755.31
    +2.19 (+0.29%)
     

  • GBP/EUR

    1.1655
    -0.0001 (-0.01%)
     

  • GBP/USD

    1.2506
    -0.0005 (-0.04%)
     

  • Bitcoin GBP

    51,450.27
    +344.99 (+0.68%)
     

  • CMC Crypto 200

    1,391.11
    -5.42 (-0.39%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.05
    +0.48 (+0.57%)
     

  • GOLD FUTURES

    2,356.20
    +13.70 (+0.58%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,634.09
    +349.55 (+2.02%)
     

  • DAX

    18,014.44
    +97.16 (+0.54%)
     

  • CAC 40

    8,036.86
    +20.21 (+0.25%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Gene therapy takes step forward as GSK files for EU approval

Reuters - UK Focus

LONDON, May 5 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) said on Tuesday it had submitted a gene therapy for approval in Europe, becoming the first big drugmaker to seek marketing authorisation for the technology to fix faulty genes.

Reuters reported last week that the move was imminent. It marks the latest sign of a renaissance in gene therapy after some disastrous clinical trial results in the late 1990s and early 2000s.

GSK's product, developed with Italian scientists, is designed to treat a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID) for whom no suitable bone marrow donor can be found.

(Reporting by Ben Hirschler; editing by Jason Neely)